UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 42.

Itin, P; Bosshard, P; Toutous-Trellu, L; Schmidt, A J; Vernazza, P; Tarr, P; Stoeckle, M; Wymann, M P; Ciardo, D; Walser, S; Claass, J; Scheidegger, C; Lowe, N; Oertle-Meyer, D; Cavassini, M; Schmid, P; Bernasconi, E; Haerry, D; Boffi-El Amari, E; Herold, M; Klimkait, T; Kahlert, C; Furrer, H J; Lautenschlager, S; Calmy, A; Fehr, J (2015). Syphilis: diagnostic and treatment. Swiss Medical Forum, 19:459-465.

Hasse, B; Iff, M; Ledergerber, B; Calmy, A; Schmid, P; Hauser, C; Cavassini, M; Bernasconi, E; Marzolini, C; Tarr, P E; Aubert, V; Barth, J; Battegay, M; Bernasconi, E; Boni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Egger, M; Elzi, L; Fehr, J; Fellay, J; Furrer, H; Fux, C A; Gorgievski, M; Gunthard, H; Haerry, D; Hasse, B; Hirsch, H H; Hosli, I; Kahlert, C; Kaiser, L; Keiser, O; Klimkait, T; Kouyos, R; Kovari, H; Ledergerber, B; Martinetti, G; Martinez de Tejada, B; Metzner, K; Muller, N; Nadal, D; Pantaleo, G; Rauch, A; Regenass, S; Rickenbach, M; Rudin, C; Schoni-Affolter, F; Schmid, P; Schultze, D; Schupbach, J; Speck, R; Staehelin, C; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2):ofu040.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Marzolini, C; Back, D; Weber, R; Furrer, H; Cavassini, M; Calmy, A; Vernazza, P; Bernasconi, E; Khoo, S; Battegay, M; Elzi, L (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9):2107-2111.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

El Amari, E B; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV Medicine, 12(7):394-402.

von Wyl, V; Gianella, S; Fischer, M; Niederoest, B; Kuster, H; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11):e27463.

Gianella, S; von Wyl, V; Fischer, M; Niederoest, B; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy, 16(4):535-545.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

Kaufmann, G R; Elzi, L; Weber, R; Furrer, H; Giulieri, S; Vernazza, P; Bernasconi, E; Hirschel, B; Battegay, M (2011). Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS, 25(4):441-451.

Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E (2011). Lipid and lipoprotein profile in HIV-infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. AIDS Research and Human Retroviruses, 27(5):525-533.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Lubomirov, R; di Iulio, J; Fayet, A; Colombo, S; Martinez, R; Marzolini, C; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Ledergerber, B; Rentsch, K; Descombes, P; Buclin, Thierry; Decosterd, L A; Csajka, C; Telenti, A (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 20(4):217-230.

Audigé, A; Schlaepfer, E; von Wyl, V; Miller, R C; Vernazza, P; Nadal, D; Speck, R F (2010). B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering. AIDS Research and Human Retroviruses, 26(10):1063-1074.

Hasse, B; Ledergerber, B; Hirschel, B; Vernazza, P; Glass, T R; Jeannin, A; Evison, J M; Elzi, L; Cavassini, M; Bernasconi, E; Nicca, D; Weber, R (2010). Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 51(11):1314-1322.

Rotger, M; Gsponer, T; Martinez, R; Taffé, P; Elzi, L; Vernazza, P; Cavassini, M; Bernasconi, E; Hirschel, B; Furrer, H; Weber, R; Ledergerber, B; Egger, M; Telenti, A; Tarr, P E; Swiss HIV Cohort Study (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clinical Infectious Diseases, 51(9):1090-1098.

Kovari, H; Ledergerber, B; Battegay, M; Rauch, A; Hirschel, B; Foguena, A K; Vernazza, P; Bernasconi, E; Mueller, N J; Weber, R (2010). Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clinical Infectious Diseases, 50(4):502-511.

Audigé, A; Taffé, P; Rickenbach, M; Battegay, M; Vernazza, P; Nadal, D; Speck, R (2010). Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. AIDS Research and Human Retroviruses, 26(9):997-1005.

Marzolini, C; Elzi, L; Gibbons, S; Weber, R; Fux, C; Furrer, H; Chave, J P; Cavassini, M; Bernasconi, E; Calmy, A; Vernazza, P; Khoo, S; Ledergerber, B; Back, D; Battegay, M (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3):413-423.

Bucher, H C; Rickenbach, M; Young, J; Glass, T R; Vallet, Y; Bernasconi, E; Cavassini, M; Fux, C; Schiffer, V; Vernazza, P; Weber, R; Battegay, M (2010). Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 15(1):31-40.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Elzi, L; Kaufmann, G; Weber, R; Fux, C A; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M (2009). Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clinical Trials, 10(4):207-214.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Khanna, N; Elzi, L; Mueller, N J; Garzoni, C; Cavassini, M; Fux, C A; Vernazza, P; Bernasconi, E; Battegay, M; Hirsch, H H (2009). Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clinical Infectious Diseases, 48(10):1459-1466.

Khanna, N; Wolbers, M; Mueller, N J; Garzoni, C; Du Pasquier, R A; Fux, C A; Vernazza, P; Bernasconi, E; Viscidi, R; Battegay, M; Hirsch, H H (2009). JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. Journal of Virology, 83(9):4404-4411.

Bellini, C; Keiser, O; Chave, J P; Evison, Jm; Fehr, J; Kaiser, L; Weber, R; Vernazza, P; Bernasconi, E; Telenti, A; Cavassini, M (2009). Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 10(1):12-18.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Daneel, S; Schüpbach, J; Gebhardt, M; Werner, M; Staub, R; Vernazza, P (2008). A prospective evaluation of the feasibility and utility of additional tools to obtain information from recently diagnosed HIV infected patients. Swiss Medical Weekly, 138(31-32):453-458.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

El Amari, E B; Toutous-Trellu, L; Gayet-Ageron, A; Baumann, M; Cathomas, G; Steffen, I; Erb, P; Mueller, N J; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2008). Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS, 22(9):1019-1028.

Berger, S; Schad, T; von Wyl, V; Ehlert, Ulrike; Zellweger, C; Furrer, H; Regli, D; Ledergerber, B; Battegay, M; Weber, R; Gaab, J; Vernazza, P (2008). Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS, 22(6):767-775.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

Schüpbach, J; Gebhardt, M D; Tomasik, Z; Niederhauser, C; Yerly, S; Bürgisser, P; Matter, L; Gorgievski, M; Dubs, R; Schultze, D; Steffen, I; Andreutti, C; Martinetti, G; Güntert, B; Staub, R; Daneel, S; Vernazza, P (2007). Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Medicine, 4(12):e343.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

Bürgisser, P; Vernazza, P; Flepp, M; Böni, J; Tomasik, Z; Hummel, U; Pantaleo, G; Schüpbach, J (2000). Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 23(2):138-144.

This list was generated on Fri Jul 21 19:21:39 2017 CEST.